ACADIA PHARMACEUTICALS INC (ACAD) Fundamental Analysis & Valuation

NASDAQ:ACAD • US0042251084

Current stock price

22.04 USD
+0.58 (+2.7%)
Last:

This ACAD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. ACAD Profitability Analysis

1.1 Basic Checks

  • ACAD had positive earnings in the past year.
  • ACAD had a positive operating cash flow in the past year.
  • In the past 5 years ACAD reported 4 times negative net income.
  • ACAD had negative operating cash flow in 4 of the past 5 years.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 25.00%, ACAD belongs to the top of the industry, outperforming 97.09% of the companies in the same industry.
  • ACAD's Return On Equity of 31.86% is amongst the best of the industry. ACAD outperforms 96.90% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 6.43%, ACAD belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
Industry RankSector Rank
ROA 25%
ROE 31.86%
ROIC 6.43%
ROA(3y)-2.12%
ROA(5y)-7.86%
ROE(3y)0.06%
ROE(5y)-7.96%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

1.3 Margins

  • ACAD has a Profit Margin of 36.49%. This is amongst the best in the industry. ACAD outperforms 96.71% of its industry peers.
  • In the last couple of years the Profit Margin of ACAD has declined.
  • ACAD has a Operating Margin of 9.78%. This is amongst the best in the industry. ACAD outperforms 89.92% of its industry peers.
  • In the last couple of years the Operating Margin of ACAD has declined.
  • With an excellent Gross Margin value of 91.69%, ACAD belongs to the best of the industry, outperforming 93.22% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
Industry RankSector Rank
OM 9.78%
PM (TTM) 36.49%
GM 91.69%
OM growth 3Y-58.8%
OM growth 5YN/A
PM growth 3Y-26.93%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-0.78%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ACAD Health Analysis

2.1 Basic Checks

  • ACAD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ACAD has less shares outstanding
  • The number of shares outstanding for ACAD has been increased compared to 5 years ago.
  • ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 6.40 indicates that ACAD is not in any danger for bankruptcy at the moment.
  • ACAD has a better Altman-Z score (6.40) than 75.97% of its industry peers.
  • There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.4
ROIC/WACC0.7
WACC9.15%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • ACAD has a Current Ratio of 3.83. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
  • ACAD has a Current ratio (3.83) which is in line with its industry peers.
  • ACAD has a Quick Ratio of 3.71. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.71, ACAD is in line with its industry, outperforming 48.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.71
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ACAD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 377.08% over the past year.
  • ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 113.98%.
  • ACAD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.39% yearly.
EPS 1Y (TTM)377.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8100%
Revenue 1Y (TTM)113.98%
Revenue growth 3YN/A
Revenue growth 5Y19.39%
Sales Q2Q%9.39%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.61% on average over the next years.
  • The Revenue is expected to grow by 11.19% on average over the next years. This is quite good.
EPS Next Y-78.31%
EPS Next 2Y-34.05%
EPS Next 3Y-9.81%
EPS Next 5Y6.61%
Revenue Next Year15.61%
Revenue Next 2Y13.59%
Revenue Next 3Y13.33%
Revenue Next 5Y11.19%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 500M 1B 1.5B 2B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. ACAD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.62, the valuation of ACAD can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 96.90% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.18, ACAD is valued rather cheaply.
  • ACAD is valuated quite expensively with a Price/Forward Earnings ratio of 44.38.
  • Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 90.70% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 37.96. ACAD is around the same levels.
Industry RankSector Rank
PE 9.62
Fwd PE 44.38
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • 94.57% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
  • ACAD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ACAD is cheaper than 88.76% of the companies in the same industry.
Industry RankSector Rank
P/FCF 595.69
EV/EBITDA 13.34
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • ACAD has a very decent profitability rating, which may justify a higher PE ratio.
  • ACAD's earnings are expected to decrease with -9.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.05%
EPS Next 3Y-9.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACAD Dividend Analysis

5.1 Amount

  • ACAD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACAD Fundamentals: All Metrics, Ratios and Statistics

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (4/14/2026, 1:17:09 PM)

22.04

+0.58 (+2.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners98.69%
Inst Owner Change-0.01%
Ins Owners0.28%
Ins Owner Change1.82%
Market Cap3.76B
Revenue(TTM)1.07B
Net Income(TTM)391.00M
Analysts80
Price Target32.37 (46.87%)
Short Float %6.33%
Short Ratio5.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)611.18%
Min EPS beat(2)178.22%
Max EPS beat(2)1044.15%
EPS beat(4)3
Avg EPS beat(4)308.41%
Min EPS beat(4)-3.19%
Max EPS beat(4)1044.15%
EPS beat(8)6
Avg EPS beat(8)160.73%
EPS beat(12)8
Avg EPS beat(12)114.4%
EPS beat(16)11
Avg EPS beat(16)90.18%
Revenue beat(2)0
Avg Revenue beat(2)-3.01%
Min Revenue beat(2)-4.84%
Max Revenue beat(2)-1.19%
Revenue beat(4)1
Avg Revenue beat(4)-1.72%
Min Revenue beat(4)-4.84%
Max Revenue beat(4)0.08%
Revenue beat(8)2
Avg Revenue beat(8)-2.38%
Revenue beat(12)5
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)0.67%
PT rev (3m)8.06%
EPS NQ rev (1m)-3.58%
EPS NQ rev (3m)-38.4%
EPS NY rev (1m)-1.82%
EPS NY rev (3m)-38.33%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)-0.14%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)3.58%
Valuation
Industry RankSector Rank
PE 9.62
Fwd PE 44.38
P/S 3.51
P/FCF 595.69
P/OCF 34.21
P/B 3.06
P/tB 3.36
EV/EBITDA 13.34
EPS(TTM)2.29
EY10.39%
EPS(NY)0.5
Fwd EY2.25%
FCF(TTM)0.04
FCFY0.17%
OCF(TTM)0.64
OCFY2.92%
SpS6.28
BVpS7.2
TBVpS6.56
PEG (NY)N/A
PEG (5Y)N/A
Graham Number19.26
Profitability
Industry RankSector Rank
ROA 25%
ROE 31.86%
ROCE 8.14%
ROIC 6.43%
ROICexc N/A
ROICexgc N/A
OM 9.78%
PM (TTM) 36.49%
GM 91.69%
FCFM 0.59%
ROA(3y)-2.12%
ROA(5y)-7.86%
ROE(3y)0.06%
ROE(5y)-7.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-58.8%
OM growth 5YN/A
PM growth 3Y-26.93%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-0.78%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 880.34%
Cap/Sales 9.66%
Interest Coverage 250
Cash Conversion 94.22%
Profit Quality 1.61%
Current Ratio 3.83
Quick Ratio 3.71
Altman-Z 6.4
F-Score3
WACC9.15%
ROIC/WACC0.7
Cap/Depr(3y)535%
Cap/Depr(5y)327.69%
Cap/Sales(3y)570.92%
Cap/Sales(5y)342.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)377.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8100%
EPS Next Y-78.31%
EPS Next 2Y-34.05%
EPS Next 3Y-9.81%
EPS Next 5Y6.61%
Revenue 1Y (TTM)113.98%
Revenue growth 3YN/A
Revenue growth 5Y19.39%
Sales Q2Q%9.39%
Revenue Next Year15.61%
Revenue Next 2Y13.59%
Revenue Next 3Y13.33%
Revenue Next 5Y11.19%
EBIT growth 1Y201.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.58%
EBIT Next 3Y52.42%
EBIT Next 5Y44.2%
FCF growth 1Y549.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7923.08%
OCF growth 3YN/A
OCF growth 5YN/A

ACADIA PHARMACEUTICALS INC / ACAD Fundamental Analysis FAQ

What is the fundamental rating for ACAD stock?

ChartMill assigns a fundamental rating of 6 / 10 to ACAD.


What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?

ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.


What is the profitability of ACAD stock?

ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.


Can you provide the financial health for ACAD stock?

The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 8 / 10.